Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 3 of 26 for:    DX-2930

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01923207
Recruitment Status : Completed
First Posted : August 15, 2013
Last Update Posted : May 17, 2021
Dyax Corp.
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.

Condition or disease Intervention/treatment Phase
Hereditary Angioedema (HAE) Drug: DX-2930 Drug: Placebo Phase 1

Detailed Description:
Approximately 32 healthy subjects will be randomized to receive DX-2930 or placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects
Actual Study Start Date : August 12, 2013
Actual Primary Completion Date : January 7, 2014
Actual Study Completion Date : January 7, 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: DX-2930
DX-2930 administered by subcutaneous route
Drug: DX-2930
Placebo Comparator: placebo
inactive formulation of DX-2930
Drug: Placebo
placebo, subcutaneous administration

Primary Outcome Measures :
  1. Proportion of subjects with adverse events [ Time Frame: 112 days ]

Secondary Outcome Measures :
  1. DX-2930 plasma level [ Time Frame: 112 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male or female subjects who are 18 to 55 years of age, inclusive.
  2. Willing and able to read, understand, and sign an informed consent form.
  3. Willing and able to receive subcutaneous injections.
  4. Body mass index (BMI) of 18 to 33 kg/m2 with a weight of at least 60 kg for males and at least 50 kg for females, with a maximum weight of 130 kg for any subject.
  5. Medically healthy as determined by the investigator via assessment of physical examination, medical history, clinical laboratory tests, vital signs, and electrocardiogram (ECG).
  6. Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through 30 days after the final study visit: condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or intra-uterine device (IUD). A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Female subjects must agree to practice the above birth control methods for 30 days after the final study visit as a safety precaution.
  7. Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening follicle-stimulating hormone (FSH) level in the post-menopausal range), do not require contraception during the study.
  8. Males with female partners of childbearing potential must agree to use a highly effective, medically acceptable form of contraception from the screening period through 60 days after the final study visit. All male subjects, including males who are surgically sterile (post vasectomy), must agree to practice the above birth control methods for 60 days from the final study visit as a safety precaution.

Exclusion Criteria:

  1. Any active acute or chronic illness at screening.
  2. Any history of exposure to a biologic within 90 days prior to dosing.
  3. Receipt of any investigational (a non-licensed, non-approved) drug or device within 60 days prior to dosing.
  4. Any prior history of exposure to a monoclonal antibody.
  5. Pregnant or actively breastfeeding.
  6. Any history of substance abuse or dependence.
  7. Positive urine drug or alcohol test at screening or Day -1 for amphetamines, benzodiazepines, barbiturates, cocaine, cotinine (detection mechanism for nicotine), marijuana, opiates, phencyclidine or ethanol.
  8. Regular use of alcohol within six months prior to the screening visit [more than fourteen units of alcohol per week (1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol)].
  9. Use of prescription or over-the-counter medication within 14 days prior to administration of study medication, or use of over-the-counter products (dietary or herbal supplements and vitamins) within 14 days prior to administration of study medication.
  10. Use of nicotine or nicotine-containing products within the previous three months prior to screening.
  11. Subject has any other condition, which in the opinion of the investigator may compromise the safety or compliance or would preclude the subject from successful completion of the study or interfere with the interpretation of the results.
  12. Abnormal clinical laboratory values and/or other study assessments such as ECG results deemed to be clinically significant by the investigator.
  13. Donation of blood within 60 days preceding Study Day -1.
  14. Serology testing positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01923207

Layout table for location information
United States, Kansas
Vince and Associates Clinical Research
Overland Park, Kansas, United States, 66212
Sponsors and Collaborators
Dyax Corp.
Layout table for investigator information
Study Director: Study Director Takeda
Publications of Results:
Layout table for additonal information
Responsible Party: Shire Identifier: NCT01923207    
Other Study ID Numbers: DX-2930-01
First Posted: August 15, 2013    Key Record Dates
Last Update Posted: May 17, 2021
Last Verified: May 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Hereditary Complement Deficiency Diseases
Primary Immunodeficiency Diseases
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes